Vaccine

Advanced Health Intelligence Ltd Signs Collaboration Agreement with IntelliGen FZ-LLCAdvanced Health Intelligence Ltd Signs Collaboration Agreement with IntelliGen FZ-LLC

Advanced Health Intelligence Ltd Signs Collaboration Agreement with IntelliGen FZ-LLC

Highlights AHI enters a second commercial agreement in the UAE.IntelliGen Founders have worked with, and within the Government, Healthcare needs…

2 years ago
BiondVax Reports Second Quarter Financial Results and Provides Business UpdateBiondVax Reports Second Quarter Financial Results and Provides Business Update

BiondVax Reports Second Quarter Financial Results and Provides Business Update

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on…

2 years ago
cbdMD Demonstrates Strong Year-over-Year Performance, Significantly Reducing Net Loss by $30 MillioncbdMD Demonstrates Strong Year-over-Year Performance, Significantly Reducing Net Loss by $30 Million

cbdMD Demonstrates Strong Year-over-Year Performance, Significantly Reducing Net Loss by $30 Million

Charlotte, North Carolina--(Newsfile Corp. - August 10, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the…

2 years ago
Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial ProductsBlue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial Products

Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water’s Commercial Products

CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical…

2 years ago
Inovalon Achieves NCQA HEDIS® Measure Certification for the 23rd Consecutive YearInovalon Achieves NCQA HEDIS® Measure Certification for the 23rd Consecutive Year

Inovalon Achieves NCQA HEDIS® Measure Certification for the 23rd Consecutive Year

Inovalon Converged Quality, Cloud Software Empowers More Than 80% of the Nation’s Clinical Outcomes Measurement AnalyticsBOWIE, Md., Aug. 10, 2023…

2 years ago
Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple CancersOcean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr.…

2 years ago
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseaseVaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the…

2 years ago
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business UpdateIMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call…

2 years ago
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsVaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…

2 years ago
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsHOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and…

2 years ago